Table 1 Characteristics of 204 patients with ankylosing spondylitis in western Sweden
From: Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment
Patients, number (%) | Median (range) | Mean ± SD | ||
|---|---|---|---|---|
Demographic variables | ||||
Sex | Women | 87 (43) | ||
Men | 117 (57) | |||
Age, years | NA | 49 (17 to 78) | 50 ± 13 | |
Postmenopausal women | 45/87 (52) | |||
Heredity for fractures | 57 (28) | |||
History of vertebral fracture | 3 (1) | |||
History of non-vertebral fracture | 18 (9) | |||
Current smokers | 24 (12) | |||
Ever smoked > 6 months | 101 (50) | |||
Daily calcium intake from dairy products | NA | 600 (0 to 2,640) | 668 ± 397 | |
BMI, kg/m2 | 25 (19 to 46) | 26 ± 4 | ||
LTPAI total, hours | 6 (0 to 42) | 7 ± 6 | ||
PAHWI total, hours | 45 (0 to 160) | 40 ± 21 | ||
FRAX major osteoporotic fracture (%) (patients ≥ 40 years) | 6.7 (1.2 to 68.0) | 9.9 ± 9.7 | ||
FRAX hip fracture (%) (patients ≥ 40 years) | 0.8 (0 to 56.0) | 2.4 ± 6.0 | ||
Disease-related variables | ||||
Years since onset of symptoms | 24 (2 to 55) | 24 ± 13 | ||
Years since diagnosis | 12 (1 to 47) | 15 ± 11 | ||
History of anterior uveitis | 102 (50) | |||
History of peripheral arthritis | 120 (59) | |||
History of coxitis | 17 (8) | |||
BASMI, score | 3.0 (0.6 to 7.4) | 3.1 ± 1.6 | ||
BASDAI, score | 3.5 (0.0 to 9.6) | 3.6 ± 2.1 | ||
BASFI, score | 2.3 (0.0 to 8.7) | 2.7 ± 2.1 | ||
BAS-G1, score (last week) | 2.9 (0.0 to 10.0) | 3.4 ± 2.6 | ||
BAS-G2, score (last 6 months) | 3.4 (0.0 to 9.7) | 3.8 ± 2.6 | ||
ASDAS, score | 2.3 (0.8 to 5.9) | 2.4 ± 0.9 | ||
mSASSS, score | 5.5 (0.0 to 72.0) | 14.2 ± 19.2 | ||
Mean ESR, mm/h (2004 to 2008) | 16 (2 to 102) | 19 ± 15 | ||
ESR, mm/h (at inclusion 2009) | 11 (2 to 105) | 15 ± 14 | ||
CRP, mg/L | 5 (3 to 80) | 9 ± 10 | ||
Hemoglobin, g/L | 139 (105 to 166) | 139 ± 13 | ||
WBC, × 109/L | 6.7 (2.7 to 18.1) | 7.0 ± 2.1 | ||
PLT, × 109/L | 287 (133 to 506) | 299 ± 75 | ||
Creatinine, μmol/L | 70 (43 to 148) | 71 ± 15 | ||
HLA-B27 positive | 178 (87) | |||
Patients on NSAID | 158 (77) | |||
Patients on DMARD | 62 (30) | |||
Patients on TNF inhibitor | 42 (21) | |||
Patients on GC | 7 (3) | |||
GC lifetime use, mg prednisone | NA | 100 (0, 56390) | 1397 ± 5775 | |
Patients on bisphosphonates | 8 (4) | |||
Patients on HRT | 5 (2) | |||
Patients on calcium and vitamin D | 24 (12) | |||
Bone mineral density | ||||
aBMD AP lumbar spine, g/cm2 | 1.02 (0.63 to 1.54) | 1.02 ± 0.17 | ||
aBMD lateral lumbar spine, g/cm2 | 0.72 (0.32 to 1.13) | 0.73 ± 0.14 | ||
vBMD lumbar spine, g/cm3 | 0.19 (0.09 to 0.27) | 0.19 ± 0.03 | ||
BMD total hip, g/cm2 | 0.93 (0.54 to 1.42) | 0.94 ± 0.14 | ||
BMD femoral neck, g/cm2 | 0.78 (0.48 to 1.20) | 0.78 ± 0.13 | ||
BMD radius total, g/cm2 | 0.61 (0.40 to 0.78) | 0.61 ± 0.08 | ||